Alumis Announces Its Phase 2b LUMUS Study Of Envudeucitinib To Treat Lupus Erythematosus Failed To Meet Primary, Secondary Endpoints
Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that its Phase 2b LUMUS trial of
Alumis tested a new medicine for lupus, but it didn't work as well as hoped in the big trial. When a medicine doesn't show it actually helps patients the way doctors expected, it's a sign the company has to go back to the drawing board.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.